Browse Clinical Trials in New York

Explore actively recruiting studies pulled live from the public ClinicalTrials.gov registry. Filter by condition and state, then check your eligibility in under a minute.

Matching trials

4 recruiting in NY

Recruiting

Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry

Rheumatic Joint Disease

Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including safety questions.

Albany, Lake Success +more, NYUp to 21 yrsAll genders

See details & check eligibility

Recruiting

Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients

Psoriatic Arthritis

The trial is an open-label randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an inadequate response to a TNFi.

New York, NY18–80 yrsAll genders

See details & check eligibility

Recruiting

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

Plaque Psoriasis

A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis

Kew Gardens, New City +more, NY40+ yrsAll genders

See details & check eligibility

Recruiting

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

Atopic Dermatitis

This is a Phase 1b, randomized, placebo/vehicle-controlled, double-blinded, multi-center trial. It is designed to assess the safety and efficacy of S. hominis A9 (ShA9) topical application as a treatment for atopic dermatitis (AD). The trial will enroll adults and pediatric participants with atopic dermatitis. The primary safety objective of this study is to compare the safety profile of ShA9 to placebo (vehicle) over 14 weeks of application, which includes an initial two-week period of co-treatment with topical corticosteroids (TCS). The primary efficacy objective of this study is to assess the ability of ShA9, compared to placebo (vehicle), to prolong the period of atopic dermatitis control over 12 weeks after conclusion of an initial two-week period of co-treatment with TCS.

New York, Rochester +more, NY6+ yrsAll genders

See details & check eligibility